Bhattacharyya N, Ramsammy R, Eatman E, Hollis V W, Anderson W A
Department of Biology, Howard University, Washington, D.C. 20059.
J Submicrosc Cytol Pathol. 1994 Apr;26(2):147-62.
The mechanism(s) by which estrogen regulates cell growth in target cells and the cascade of biochemical changes associated with growth have not yet been fully determined. Equally undetermined is an understanding of the mechanism(s) by which tamoxifen blocks estrogen-regulated growth. This study, therefore, attempts to define and correlate the physiological processes in the rat uterus following estrogen and tamoxifen administration with temporal events manifested by mRNA expression of protooncogenes (m-myc, c-ras, c-fos, c-jun), growth factors and/or inhibins (IGF-1, IGF-2, IGF-2 Exon 1 and Exon 2), EGF, TGFB-1, -2, -3), growth factor or inhibin receptors (EGFr, TGFB-2r, TGFB-3r), and estrogen-induced differentiative proteins including estrogen receptor (ER), progesterone receptor (PR). In this study, mRNA was isolated from hormone and antagonist-treated rat uteri at 0', 15', 30', 1 h, 6 h, 24 h, 48 h and 72 h. Expression studies were analysed by dot/Northern blot hybridization with cDNA or oligonucleotide probes for the RNAs mentioned above. Nuclear runoff transcriptional assays were also performed. Our data suggest that fos, myc, ras and jun protooncogenes were expressed from 15' to 48 h after treatment with either estrogen or tamoxifen. Tamoxifen treatment resulted in diminished expression, but incomplete inhibition of the protooncogene mRNAs. Estrogen treatment resulted in rapid elevation of both EGF and EGFr mRNA levels, both of which were suppressed after tamoxifen treatment. Tamoxifen may exert its antiestrogenic effects by inhibiting EGF and EGFr, and myc protooncogene activity on the one hand, and by overexpression of the TGFB isotypes and their receptors on the other hand. With the proliferation cycle short circuited, tamoxifen-treated cells hypertrophied and differentiated to terminal cells by 24-48 h. Working hypotheses for the mechanisms of action of estrogen and tamoxifen are presented based on our data.
雌激素调节靶细胞中细胞生长的机制以及与生长相关的一系列生化变化尚未完全明确。同样未确定的是对他莫昔芬阻断雌激素调节生长的机制的理解。因此,本研究试图确定并关联大鼠子宫在给予雌激素和他莫昔芬后发生的生理过程,以及原癌基因(m-myc、c-ras、c-fos、c-jun)、生长因子和/或抑制素(IGF-1、IGF-2、IGF-2外显子1和外显子2)、表皮生长因子(EGF)、转化生长因子β-1、-2、-3)、生长因子或抑制素受体(EGFr、TGFβ-2r、TGFβ-3r)以及雌激素诱导的分化蛋白(包括雌激素受体(ER)、孕激素受体(PR))的mRNA表达所体现的时间事件。在本研究中,在0分钟、15分钟、30分钟、1小时、6小时、24小时、48小时和72小时从经激素和拮抗剂处理的大鼠子宫中分离mRNA。通过用上述RNA的cDNA或寡核苷酸探针进行点/ Northern印迹杂交分析表达研究。还进行了核转录延伸分析。我们的数据表明,在用雌激素或他莫昔芬处理后15分钟至48小时,fos、myc、ras和jun原癌基因表达。他莫昔芬处理导致原癌基因mRNA表达减少,但未完全抑制。雌激素处理导致EGF和EGFr mRNA水平迅速升高,而在他莫昔芬处理后两者均受到抑制。他莫昔芬可能一方面通过抑制EGF和EGFr以及myc原癌基因活性,另一方面通过TGFβ同种型及其受体的过表达发挥其抗雌激素作用。由于增殖周期短路,他莫昔芬处理的细胞在24 - 48小时内肥大并分化为终末细胞。基于我们的数据提出了雌激素和他莫昔芬作用机制的工作假说。